Research programme: tankyrase inhibitors - Merck Serono/The Institute of Cancer Research
Latest Information Update: 09 Oct 2014
At a glance
- Originator Merck Serono; The Institute of Cancer Research
- Class Small molecules
- Mechanism of Action Tankyrase inhibitors; Wnt signalling pathway inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 07 Oct 2014 Preclinical trials in Cancer in Germany (unspecified route)
- 07 Oct 2014 Preclinical trials in Cancer in United Kingdom (unspecified route)